Charme Capital Partners, a mid-market private equity fund, agreed to acquire a majority stake in Tema Sinergie, a manufacturer of innovative products for nuclear medicine applications. Financial terms were not disclosed. "Charme IV's investment in Tema Sinergie is totally consistent with Charme Funds strategy of investing, in partnership with their respective founders and managers, in excellent entrepreneurial companies with strong growth potential. The leadership and vision of the founders and of Stefano Piancastelli are, in total continuity, the pillars of the significant growth envisaged in the strategic plan of Tema Sinergie," Tommaso Beolchini, Charme Founding Partner.